Abstract
The management of young arthritic knee and early grades of osteoarthritis (OA) aims to reduce morbidity and improve the quality of life for which newer modalities are emerging. Orthobiologics have emerged as a viable alternative option as they promote tissue regeneration and could be potential disease-modifying agents. Platelet-rich plasma (PRP) has been promising and is among the frontline treatment options in early OA knee; newer orthobiologic research is progressing beyond this and newer products are being tried. Various combinations of PRP with carriers and growth factor extracts from PRP are some new developments. Additional options beyond PRP include autologous conditioned serum, alpha-2 macroglobulin, adipose tissue derivative, bone marrow aspirate concentrate, and gene therapy. This review aims to shed light on the current literature and future potential of the use of these intra-articular orthobiologics in the 21st century.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.